Development of DNA topoisomerase II-mediated anticancer agents, 3-(9-acridinylamino)-5-hydroxymethylanilines (AHMAs) and related compounds.
A series of potential topoisomerase II-mediated anticancer 9-anilinoacridine derivatives, which are designed to avoid bio-oxidation and possessed long duration of drug action, is reviewed. Among these agents, 3-(9-acridinylamino)-5-hydroxymethylaniline (AHMA) derivatives and their alkylcarbamates have been investigated and developed for potential clinical application.
Su
Tsann-Long
TL
Laboratory of Bioorganic Chemistry, Institute of Biomedical Sciences, Academia Sinica, Taipei, 115, Taiwan. tlsu@ibms.sinica.edu.tw
D000166:Acridines / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D000814:Aniline Compounds / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology*; D004247:DNA / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D010084:Oxidation-Reduction; D013329:Structure-Activity Relationship; D059005:Topoisomerase II Inhibitors
C466640:3-(9-acridinylamino)-5-hydroxymethylaniline; D000166:Acridines; D000814:Aniline Compounds; D000970:Antineoplastic Agents; D059005:Topoisomerase II Inhibitors; D004247:DNA